Diabetes

A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.

Research presented at the American Diabetes Association's 80th Scientific Sessions offers new insights into the future of glycemic control, diabetes self-management, and remote care.

In this episode of Managed Care Cast, we speak with the lead author of a study in the June issue of The American Journal of Managed Care® about the nationwide dearth of suppliers of the Medicare Diabetes Prevention Program, which aims to reach older adults with prediabetes.

Selected abstracts from the American Diabetes Association's 80th Scientific Sessions discuss when to add injectable therapy, how patients who switched to semaglutide lost more weight and gained glycemic control, and offered results from an early-phase study on a monoclonal antibody that may preserve B-cell function.

During a joint symposium on Saturday, held as part of the 80th American Diabetes Association Scientific Sessions and hosted by JDRF President and CEO Aaron Kowalski, PhD, experts debated the merits and pitfalls of how to measure glycemic control and overall health among persons with diabetes. Which is better, they asked: the traditional measure of glycated hemoglobin or the newer measure, time-in-range?

The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

American women die in childbirth at a higher rate than in any other developed country, while non-Hispanic Black women are more than 3 times more likely to have a maternal death than white women in the United States, according to a review presented at the American Diabetes Association’s 80th Scientific Sessions.

Obesity contributes to development of youth-onset type 2 diabetes (T2D) and can lead to detrimental health outcomes in adulthood. Researchers explored this relationship and offered insights on addressing the problem during a session at the American Diabetes Association’s (ADA) 80th Scientific sessions, held virtually due to coronavirus disease 2019 (COVID-19).

The aim of this feasibility study was to determine whether digital health use via smartphones, a platform that adolescents are more engaged with than other age groups, could aid in teaching youth more about cardiovascular risks, and promote uptake of this knowledge so individuals increase heart healthy behaviors, said Tara Kaushal, MD, physician and clinical researcher at Joslin Diabetes Center.

When it comes to diabetes, lead study author Deepak L. Bhatt, MD, MPH, said clinicians and payers should weigh the considerable costs of what happens when a patient suffers a heart attack or stroke when deciding on a treatment regimen.

This week, the top managed care news included HHS distributing COVID-19 funds to Medicaid and CHIP providers; the National Kidney Foundation issues a statement on health disparities and racial violence; a preview of our coverage of the American Diabetes Association 2020 Virtual Scientific Sessions.

Despite the Medicare Diabetes Prevention Program now being a covered benefit, there is inadequate availability of suppliers to reach Medicare beneficiaries with prediabetes.

One advantage of conducting an online scientific conference is that more individuals will gain access to information presented at the meeting, said Robert Gabbay, MD, PhD, the newly appointed chief medical and scientific officer of the American Diabetes Association.

Among patients with type 2 diabetes (T2D), concurrent cardiovascular-, heart failure–, or renal-related hospitalization presents significant disease burden leading to poor quality of life.

Patients hospitalized for coronavirus disease 2019 (COVID-19) who have diabetes account for more than 20% of individuals admitted to intensive care units, according to new guidance published in the Journal of Clinical Endocrinology & Metabolism.

The Association of Diabetes Care & Education Specialists (ADCES) released a consensus report outlining strategies health care stakeholders can follow to increase access to and utilization of diabetes self-management education and support (DSMES).

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Study from MDVIP shows personalized primary care reduces ER visits, hospitalizations and outpatient expenditures for diabetic population.

For individuals with both diabetes and colorectal cancer, high adherence to oral diabetes medication was associated with a significantly reduced risk of overall mortality compared with lower adherence, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.

Insulin out-of-pocket costs remained relatively flat between 2006 and 2017 among privately insured patients, despite increased insulin prices paid by insurers, according to research published in JAMA Internal Medicine.

A bill introduced yesterday by Representative Maxine Waters, with support from the American Diabetes Association, would eliminate cost sharing for patients with diabetes requiring insulin amid the coronavirus disease 2019 pandemic; White House officials have decided to not release economic projections this summer for the first time since the 1970s; CDC provides recommendations for employers returning to the workplace.

This week, the top managed care news included lower insulin costs for seniors in certain plans; discussions on the future of the Biologics Price Competition and Innovation Act; takeaways from Sharecare's Flatten the Curve Survey.

President Trump announced the plan today at the White House, accompanied by insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi, as well as AHIP and major health plans.

In the first report of its kind, researchers examined the combined effect of liraglutide and propranolol on the hearts of patients with both type 2 diabetes and cirrhosis.